Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

s, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Fanapt to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that the proposed Fanapt acquisition will be completed in the expected form or within the expected time frame or at all. Nor can there be any guarantee that Fanapt products will be approved for sale in any additional markets or that Novartis will obtain marketing rights to Fanapt in additional markets. Neither can there be any guarantee that Fanapt will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Fanapt could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN -News).  ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Celladon and certain of its ... of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report first quarter ... on Monday, May 11, 2015, followed by ... 4:30pm Eastern.Conference Call & Webcast: Monday, May ... , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... Pa. , April 27, 2015  Novira Therapeutics, ... therapies for curative treatment of chronic hepatitis B virus ... data for its lead HBV core inhibitor candidate, NVR ... Association for the Study of the Liver (EASL) in ... antiviral activity of NVR 3-778 from studies performed in ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... SAN DIEGO, May 3, 2012  Gen-Probe Incorporated (NASDAQ: ... the following three upcoming investor conferences previously announced on April ... of these investor conferences: , Deutsche Bank 37th ... 1:30 p.m. Eastern Time;  , Baird,s 2012 Growth Stock ...
... International, Inc. (Pii), a contract development and manufacturing organization ... announced today that it has made a grant to ... utilized to support pharmaceutical education for graduate students, as ... hot melt extrusion and other pharmaceutical processing technologies. ...
Cached Medicine Technology:Gen-Probe Withdraws from Previously Announced Investor Presentations 2Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research 2Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research 3
(Date:4/27/2015)... Jackson, Tennessee (PRWEB) April 27, 2015 A ... to help young people trapped in substance abuse. Programming for ... which will serve girls, is launching this summer. , The ... more than $100,000 to serve adolescents. The Youth Town Jim ... in Collierville on Monday, May 4, with tee times at ...
(Date:4/27/2015)... MD (PRWEB) April 27, 2015 Jesse ... the 2015–2020 United States Pharmacopeial Convention (USP) at the ... is Professor of Medicine at Georgetown University and the ... and Stewardship (COMPASS). , As USP President, a volunteer ... Convention Meeting. He will be a voting member, ex ...
(Date:4/27/2015)... UC Davis investigators have settled a ... inherited disorder that historically affected Ashkenazi Jews from ... populations of Semitic descent, particularly families from Saudi ... the researchers uncovered the biochemical underpinnings of Canavan ... incurable and progressively fatal neurological condition. The UC ...
(Date:4/27/2015)... Based in the Twin Cities of Minneapolis and ... insurance marketing organizations in the country focused on delivering ... as well as employer sponsored ancillary benefits. Spending two ... opportunity to consult with disability insurance carriers, helping to ... , An example of these programs include the most ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 On April 16, ... Get Rid of Stretch Marks ,” interviewed a UK ... . Stretch marks are a type of scar ... are caused by a breakdown of the elsastin and collagen ... (see: goo.gl/iRdmEe) , “Stretch mark removal with the Coolbeam ...
Breaking Medicine News(10 mins):Health News:Golf, Sermon on the Mount and More to Support Youth Town’s Jericho and Eden Programs 2Health News:Dr. Jesse Goodman Elected President of the USP Convention 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:Simplified Solutions Now Makes Disability Insurance Business With Secura Consultants Even Easier! 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2
... Inc.,(Nasdaq: NXTM ), a leading manufacturer of innovative ... its common stock and,warrants. The private placement consists of ... of $4.50 per share and warrants to purchase 1.9,million ... $5.50 per share,which price may be adjusted to $3.00 ...
... /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin Board: ... healthcare related disinfectants in China,announced today that ... of China,s,earthquake relief efforts. The Chinese government, ... on an,unprecedented scale in response to the ...
... May 23 Kellogg Company today,announced a $250,000 donation ... efforts in the Sichuan province in southwestern China.,The contribution ... be designated to support the efforts of the Red ... work ahead as people mobilize to rebuild their lives,and ...
... Center (MUMC) now offers a type of gallbladder ... belly button. It,s called single,incision laparoscopic surgery, or ... the SILS technique. One of them is Christopher ... the gallbladder through a,1cm. incision in the belly ...
... from the Peninsula Medical School in Cornwall, UK, have ... topically applied cream with visible light to destroy cancer ... is applied directly to skin cancers and pre-cancers, which ... red light is then shone on the tumour a ...
... Honor, books and DVDs to local schools, SAN ... Medal of Honor Foundation donated 5,000 copies of the,best-selling ... Call of,Duty," to California schools., The book chronicles ... nearly 20 from California, who hold our nation,s,highest award ...
Cached Medicine News:Health News:NxStage Announces $43 Million Private Placement of Equity Securities 2Health News:NxStage Announces $43 Million Private Placement of Equity Securities 3Health News:NxStage Announces $43 Million Private Placement of Equity Securities 4Health News:Linkwell Corporation Runs 24/7 Disinfectant Operations to Support China's Earthquake Relief Efforts 2Health News:Linkwell Corporation Runs 24/7 Disinfectant Operations to Support China's Earthquake Relief Efforts 3Health News:SILS Surgical Technique Now Available at MUMC 2Health News:Let there be light 2Health News:Let there be light 3Health News:TriWest Teaches California Kids About Veteran's Sacrifice, Courage 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Our 'flex' removes the apron weight from the shoulders while providing back support. Unlike other elastic backs, ours does not wrinkle up, making cleaning easier....
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
This battery-powered, single-use pulsed stimulator delivers approximately 0.7mA at 80 pulses per second and uses a subdermal needle as the grounding (anode) electrode. A "current flow" confirmation l...
Medicine Products: